Study of Pharmacokinetics and Relative Bioavalability of Roxithromycin

YAN Fang,YANG Jin,ZHAO Lu-hua,WU Meng-hua,TAN Xi-ying,PAN Juan
DOI: https://doi.org/10.3969/j.issn.1007-7693.2006.05.012
2006-01-01
Abstract:OBJECTIVE An HPLC-MS method was developed for determination of roxithromycin in human plasma to study the pharmacokinetic parameters in capsule and relative bioavailability.METHODS The plasma was added acetonitrile,vortexed and centrifuged. And the supernate was analyzed by LC-MS.A RP-column(Hypersil ODS,5μm,25cm×4.6mm) was used with a mobile phase of methanol-acetate buffer solution(pH 3.5)(85∶15).LC-ESI MS was used in the selected ion monitoring(SIM) mode with target ions at m/z 837.5 for roxithromycin and m/z 748.3 for clarithromycin. RESULTS The standard curve was linear in the range of 0.025~50μg/mL.The limited concentration was 3ng/mL and the recovery was 85.87%~95.03%.The relative bioavilability of roxithromycin capsule was(102.2±26.0)%.CONCLUSION The assay was proved to be sensitive,accurate and suitable for pharmacokinetic study of roxithromycin.The results of pharmacokinetics study after oral administration roxithromycin capsules showed that the two formulations were bio-equivalent.
What problem does this paper attempt to address?